丁丁达尼布通过调节纤维化和炎症来降低创伤后关节收缩症的严重程度
Erik Wegner1, Dennis Warnke2, Victoria Buschmann2
1Department of Orthopaedics and Traumatology, Biomatics Group, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany. wegner.erik@icloud.com.
Journal of molecular medicine (Berlin, Germany)
|September 24, 2025
概括
一种抗纤维素药物Nintedanib在老鼠模型中有效降低了关节收缩和改善了运动能力. 这种氨酸激酶抑制剂减轻了纤维化和炎症,显示出治疗创伤后关节收缩 (PTJC) 的前景.
科学领域:
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 创伤后关节收缩 (PTJC) 是一种使人虚弱的疾病,其非手术治疗选择有限.
- 纤维化和炎症是PTJC背后的关键病理过程.
- 需要有效的药理干预措施来管理PTJC.
研究的目的:
- 在大鼠模型中研究宁泰达尼布在缓解PTJC方面的疗效.
- 评估宁泰达尼布对关节运动和底层纤维化标志物的影响.
- 探索宁泰达尼布作为PTJC潜在的非手术治疗方法.
主要方法:
- 通过标准化的膝关节创伤和固定,建立了PTJC的老鼠模型.
- 随机分配的老鼠接受任天达尼布 (每天两次5毫克/公斤) 或安慰剂两周.
- 通过收缩角度和延伸力来评估关节的移动性;分子分析包括qPCR和纤维化标志物 (例如α-Sma) 的组织学.
主要成果:
- 与安慰剂相比,丁丁达尼布显著降低了缩角度 (p < 0.01) 和对膝盖延伸的抵抗力 (p < 0.05).
- 尼丁达尼布治疗导致α-Sma表达减少了11倍,这表明肌纤维细胞分化减少.
- 组织学分析显示,在接受宁泰达尼布治疗的老鼠的关节囊中,肌纤维细胞较少.
结论:
- 在PTJC的老鼠模型中,丁丁达尼布有效地减轻纤维化和炎症.
- 该药物增强了关节的移动性,并减少了关键的益纤维素基因表达.
- 这些发现支持进一步研究在PTJC治疗中临床应用的宁泰达尼布.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493